Caricamento...
Effect of once‐weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD‐2 clinical trial
The long‐acting glucagon‐like peptide‐1 receptor agonist dulaglutide acts by stimulating insulin secretion and reducing glucagon levels in a glucose‐dependent manner both in the fasting and postprandial states, resulting in reductions of both fasting glucose (FG) and postprandial glucose (PPG). In c...
Salvato in:
| Pubblicato in: | Diabetes Obes Metab |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Blackwell Publishing Ltd
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6852007/ https://ncbi.nlm.nih.gov/pubmed/31364266 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13844 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|